Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H19FN4O8 |
Molecular Weight | 558.4709 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOCN1C=C(F)C(=O)N(C(=O)C2=CC(=CC=C2)C(=O)OC3=C(C=CC(OC(=O)C4=CC=CC=C4)=N3)C#N)C1=O
InChI
InChIKey=WTSKMKRYHATLLL-UHFFFAOYSA-N
InChI=1S/C28H19FN4O8/c1-2-39-16-32-15-21(29)25(35)33(28(32)38)24(34)18-9-6-10-19(13-18)27(37)41-23-20(14-30)11-12-22(31-23)40-26(36)17-7-4-3-5-8-17/h3-13,15H,2,16H2,1H3
Emitefur or BOF-A2 is a fluorinated pyrimidine antimetabolite exerting antineoplastic properties. It is a compound composed of 5-fluorouracil (5-FU) and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation by dihydrouracil dehydrogenase in order to prolong the blood 5-FU level as well as increase selective toxicity to a tumor. Emitefur demonstrated clinical activity in preliminary studies in Japan. Emitefur development for the treatment of solid tumors has been discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7917366
a multi-center phase II study: the patients were scheduled to receive at least 2 courses of treatment, each consisting of 200 mg twice daily for 2 weeks followed by a 2-week rest period.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80149360
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
C053194
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
65910
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
m715
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000080219
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
110690-43-2
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
6850
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
C1022
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
SUB06508MIG
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
KK-37
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104592
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY | |||
|
9I50NF4AQ2
Created by
admin on Sat Dec 16 17:24:59 GMT 2023 , Edited by admin on Sat Dec 16 17:24:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY